Combination fixed-dose beta agonist and steroid inhaler as required for adults or children with mild asthma: A Cochrane systematic review

Author(s) Crossingham I.; Turner S.; Richardson R.; Webb P.; Ramakrishnan S. et al.
Source BMJ Evidence-Based Medicine; 2021
Background: In people with mild asthma poor adherence to regular therapy is common and increases the risk of exacerbations, morbidity and mortality. The use of fixed-dose combination inhalers containing an inhaled corticosteroid (ICS) and a fast-acting beta2-agonist (FABA) is established in moderate asthma, but they may also have potential utility in mild asthma. Objective(s): To evaluate the efficacy and safety of single combined FABA/ICS inhaler only used as needed in people with mild asthma. Design and setting: Cochrane meta-analysis of available trial data. Participant(s): Children aged 12+ and adults with mild asthma. 

• Available in full text at BMJ evidence-based medicine from Unpaywall